HARROW INC (HROW) Stock Fundamental Analysis

NASDAQ:HROW • US4158581094

53.59 USD
-0.59 (-1.09%)
At close: Mar 2, 2026
46.05 USD
-7.54 (-14.07%)
Pre-Market: 3/3/2026, 7:18:13 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to HROW. HROW was compared to 193 industry peers in the Pharmaceuticals industry. HROW has only an average score on both its financial health and profitability. HROW has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

  • HROW had positive earnings in the past year.
  • HROW had a positive operating cash flow in the past year.
  • In the past 5 years HROW always reported negative net income.
  • In multiple years HROW reported negative operating cash flow during the last 5 years.
HROW Yearly Net Income VS EBIT VS OCF VS FCFHROW Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M

1.2 Ratios

  • HROW has a Return On Assets of -1.37%. This is in the better half of the industry: HROW outperforms 76.68% of its industry peers.
  • HROW's Return On Equity of -10.60% is fine compared to the rest of the industry. HROW outperforms 74.09% of its industry peers.
  • HROW has a better Return On Invested Capital (7.48%) than 86.01% of its industry peers.
  • HROW had an Average Return On Invested Capital over the past 3 years of 1.25%. This is significantly below the industry average of 12.91%.
  • The 3 year average ROIC (1.25%) for HROW is below the current ROIC(7.48%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA -1.37%
ROE -10.6%
ROIC 7.48%
ROA(3y)-7.09%
ROA(5y)-9.18%
ROE(3y)-36.88%
ROE(5y)-57.31%
ROIC(3y)1.25%
ROIC(5y)1.34%
HROW Yearly ROA, ROE, ROICHROW Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

1.3 Margins

  • The Operating Margin of HROW (11.27%) is better than 84.46% of its industry peers.
  • In the last couple of years the Operating Margin of HROW has grown nicely.
  • HROW has a Gross Margin of 74.56%. This is amongst the best in the industry. HROW outperforms 81.35% of its industry peers.
  • In the last couple of years the Gross Margin of HROW has grown nicely.
Industry RankSector Rank
OM 11.27%
PM (TTM) N/A
GM 74.56%
OM growth 3Y20.78%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.21%
GM growth 5Y2.29%
HROW Yearly Profit, Operating, Gross MarginsHROW Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • HROW has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • There is no outstanding debt for HROW. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
HROW Yearly Shares OutstandingHROW Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
HROW Yearly Total Debt VS Total AssetsHROW Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

  • HROW has an Altman-Z score of 4.45. This indicates that HROW is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of HROW (4.45) is better than 73.58% of its industry peers.
  • A Debt/Equity ratio of 5.17 is on the high side and indicates that HROW has dependencies on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 5.17, HROW is doing worse than 80.83% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 5.17
Debt/FCF N/A
Altman-Z 4.45
ROIC/WACC0.8
WACC9.37%
HROW Yearly LT Debt VS Equity VS FCFHROW Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

  • HROW has a Current Ratio of 2.72. This indicates that HROW is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 2.72, HROW is in line with its industry, outperforming 48.19% of the companies in the same industry.
  • A Quick Ratio of 2.52 indicates that HROW has no problem at all paying its short term obligations.
  • The Quick ratio of HROW (2.52) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.72
Quick Ratio 2.52
HROW Yearly Current Assets VS Current LiabilitesHROW Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 125.00% over the past year.
EPS 1Y (TTM)125%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8.33%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%33.31%

3.2 Future

  • The Earnings Per Share is expected to grow by 125.08% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, HROW will show a very strong growth in Revenue. The Revenue will grow by 33.73% on average per year.
EPS Next Y1158.77%
EPS Next 2Y416.55%
EPS Next 3Y258.53%
EPS Next 5Y125.08%
Revenue Next Year42.18%
Revenue Next 2Y41.44%
Revenue Next 3Y38.66%
Revenue Next 5Y33.73%

3.3 Evolution

HROW Yearly Revenue VS EstimatesHROW Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
HROW Yearly EPS VS EstimatesHROW Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 4 6

More info and screens

Find the best growth stocksShow best growing peers

4

4. Valuation

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 487.18 indicates a quite expensive valuation of HROW.
  • Compared to the rest of the industry, the Price/Earnings ratio of HROW indicates a somewhat cheap valuation: HROW is cheaper than 76.17% of the companies listed in the same industry.
  • When comparing the Price/Earnings ratio of HROW to the average of the S&P500 Index (27.13), we can say HROW is valued expensively.
  • A Price/Forward Earnings ratio of 38.70 indicates a quite expensive valuation of HROW.
  • Based on the Price/Forward Earnings ratio, HROW is valued a bit cheaper than 71.50% of the companies in the same industry.
  • HROW is valuated rather expensively when we compare the Price/Forward Earnings ratio to 28.11, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 487.18
Fwd PE 38.7
HROW Price Earnings VS Forward Price EarningsHROW Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 100 200 300 400

4.2 Price Multiples

  • HROW's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. HROW is cheaper than 78.24% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 45.97
HROW Per share dataHROW EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The decent profitability rating of HROW may justify a higher PE ratio.
  • HROW's earnings are expected to grow with 258.53% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.42
PEG (5Y)N/A
EPS Next 2Y416.55%
EPS Next 3Y258.53%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • HROW does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

HARROW INC

NASDAQ:HROW (3/2/2026, 8:25:57 PM)

Premarket: 46.05 -7.54 (-14.07%)

53.59

-0.59 (-1.09%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-02
Earnings (Next)05-06
Inst Owners58.38%
Inst Owner Change5.3%
Ins Owners14.8%
Ins Owner Change2.47%
Market Cap1.98B
Revenue(TTM)N/A
Net Income(TTM)-4.99M
Analysts85.71
Price Target72.13 (34.6%)
Short Float %18.43%
Short Ratio10.33
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)819.91%
Min EPS beat(2)-18.12%
Max EPS beat(2)1657.94%
EPS beat(4)2
Avg EPS beat(4)222.09%
Min EPS beat(4)-970.3%
Max EPS beat(4)1657.94%
EPS beat(8)3
Avg EPS beat(8)30%
EPS beat(12)4
Avg EPS beat(12)-52.89%
EPS beat(16)5
Avg EPS beat(16)-847.87%
Revenue beat(2)0
Avg Revenue beat(2)-5.01%
Min Revenue beat(2)-5.31%
Max Revenue beat(2)-4.71%
Revenue beat(4)1
Avg Revenue beat(4)-5.43%
Min Revenue beat(4)-17.73%
Max Revenue beat(4)6.04%
Revenue beat(8)2
Avg Revenue beat(8)-3.74%
Revenue beat(12)4
Avg Revenue beat(12)-3.32%
Revenue beat(16)7
Avg Revenue beat(16)-1.63%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0.83%
EPS NQ rev (3m)-3.32%
EPS NY rev (1m)-6.43%
EPS NY rev (3m)-77.05%
Revenue NQ rev (1m)0.48%
Revenue NQ rev (3m)-0.51%
Revenue NY rev (1m)0.18%
Revenue NY rev (3m)-3.54%
Valuation
Industry RankSector Rank
PE 487.18
Fwd PE 38.7
P/S 7.94
P/FCF N/A
P/OCF 111.06
P/B 42.22
P/tB N/A
EV/EBITDA 45.97
EPS(TTM)0.11
EY0.21%
EPS(NY)1.38
Fwd EY2.58%
FCF(TTM)-0.56
FCFYN/A
OCF(TTM)0.48
OCFY0.9%
SpS6.75
BVpS1.27
TBVpS-3.43
PEG (NY)0.42
PEG (5Y)N/A
Graham Number1.77
Profitability
Industry RankSector Rank
ROA -1.37%
ROE -10.6%
ROCE 9.46%
ROIC 7.48%
ROICexc 9.96%
ROICexgc 45.18%
OM 11.27%
PM (TTM) N/A
GM 74.56%
FCFM N/A
ROA(3y)-7.09%
ROA(5y)-9.18%
ROE(3y)-36.88%
ROE(5y)-57.31%
ROIC(3y)1.25%
ROIC(5y)1.34%
ROICexc(3y)2.44%
ROICexc(5y)3.09%
ROICexgc(3y)9.66%
ROICexgc(5y)8.29%
ROCE(3y)1.58%
ROCE(5y)1.69%
ROICexgc growth 3Y16.24%
ROICexgc growth 5YN/A
ROICexc growth 3Y-9.77%
ROICexc growth 5YN/A
OM growth 3Y20.78%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.21%
GM growth 5Y2.29%
F-Score7
Asset Turnover0.69
Health
Industry RankSector Rank
Debt/Equity 5.17
Debt/FCF N/A
Debt/EBITDA 5.18
Cap/Depr 207.09%
Cap/Sales 15.46%
Interest Coverage 1.19
Cash Conversion 38.15%
Profit Quality N/A
Current Ratio 2.72
Quick Ratio 2.52
Altman-Z 4.45
F-Score7
WACC9.37%
ROIC/WACC0.8
Cap/Depr(3y)560.55%
Cap/Depr(5y)363.77%
Cap/Sales(3y)46.48%
Cap/Sales(5y)28.73%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)125%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8.33%
EPS Next Y1158.77%
EPS Next 2Y416.55%
EPS Next 3Y258.53%
EPS Next 5Y125.08%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%33.31%
Revenue Next Year42.18%
Revenue Next 2Y41.44%
Revenue Next 3Y38.66%
Revenue Next 5Y33.73%
EBIT growth 1Y428.64%
EBIT growth 3Y69.3%
EBIT growth 5YN/A
EBIT Next Year1299.14%
EBIT Next 3Y241.92%
EBIT Next 5Y132.11%
FCF growth 1Y87.15%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y308.55%
OCF growth 3YN/A
OCF growth 5YN/A

HARROW INC / HROW FAQ

Can you provide the ChartMill fundamental rating for HARROW INC?

ChartMill assigns a fundamental rating of 5 / 10 to HROW.


Can you provide the valuation status for HARROW INC?

ChartMill assigns a valuation rating of 3 / 10 to HARROW INC (HROW). This can be considered as Overvalued.


Can you provide the profitability details for HARROW INC?

HARROW INC (HROW) has a profitability rating of 6 / 10.


How financially healthy is HARROW INC?

The financial health rating of HARROW INC (HROW) is 4 / 10.


What is the expected EPS growth for HARROW INC (HROW) stock?

The Earnings per Share (EPS) of HARROW INC (HROW) is expected to grow by 1158.77% in the next year.